References
- 1. Dupuy, A., Simon, R.M. Critical Review of Published Microarray Studies for Cancer Outcome and Guidelines on Statistical Analysis and Reporting. JNCI J. Natl. Cancer Inst. 2007,99, 147-157. https://doi.org/10.1093/jnci/djk018
- 2. Elisei, R., Viola, D., Torregrossa, L et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012,97, 4390-4398. https://doi.org/10.1210/jc.2012-1775
- 3. Liu, C., Chen, T., Liu, Z. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol. 2016,14, 241. https://doi.org/10.1186/s12957-016-0979-1
- 4. Wang, N., Xu, D., Sofiadis, A et al. Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. J Clin Endocrinol Metab. 2014,99, E1571-9. https://doi.org/10.1210/jc.2014-1158
- 5. Nikiforov, Y.E., Nikiforova, M.N. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011,7, 569-580. https://doi.org/10.1038/nrendo.2011.142
- 6. Romei, C., Ciampi, R., Faviana, P et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide sym-porter genes in papillary thyroid cancer. Endocr Relat Cancer. 2008,15, 511-520. https://doi.org/10.1677/erc-07-0130
- 7. Riesco-Eizaguirre, G., Gutierrez-Martinez, P., Garcia-Cabezas, M.A et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006, 13, 257-269. https://doi.org/10.1677/erc.1.01119
- 8. George, J.R., Henderson, Y.C., Williams, M.D et al. Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC. J Clin Endocrinol Metab. 2015,100, E1550-9. https://doi.org/10.1210/jc.2015-2690
- 9. Eloy, C., Santos, J., Soares, P., Sobrinho-Simões, M. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch. 2011,459, 265.
- 10. Liu, R., Xing, M. Diagnostic and Prognostic TERT Promoter Mutations in Thyroid Fine Needle Aspiration Biopsy. Endocr. Relat. Cancer. 2014,21, 825.
- 11. Liu, X., Wu, G., Shan, Y et al. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell cycle. 2013,12, 1637-1638.
- 12. Melo, M., da Rocha, A.G., Vinagre, J et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014,99, E754-65. https://doi.org/10.1210/jc.2013-3734
- 13. Avares, C., Melo, M., Cameselle-Teijeiro, J.M et al. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome. 2016,174, R117. https://doi.org/10.1530/eje-15-0605
- 14. Xing, M., Liu, R., Liu, X et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014, 32, 2718-2726. https://doi.org/10.1200/jco.2014.55.5094
- 15. Muzza, M., Colombo, C., Rossi, S et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol. Cell. Endocrinol. 2015,399, 288-295.
- 16. Kachuri, L., Latifovic, L., Liu, G., Hung, R.J. Systematic review of genetic variation in chromosome 5p15. 33 and telo-mere length as predictive and prognostic biomarkers for lung cancer. Cancer Epidemiol. Prev. Biomarkers. 2016,25, 1537-1549.
- 17. Killedar, A., Stutz, M.D., Sobinoff, A.P et al. A common cancer risk-associated allele in the hTERT locus encodes a dominant negative inhibitor of telomerase. PLoS Genet. 2015,11.
- 18. Shen, N., Lu, Y., Wang, X et al. Association between rs2853669 in TERT gene and the risk and prognosis of human cancer: a systematic review and meta-analysis. Onco-target. 2017,8, 50864-50872. https://doi.org/10.18632/onco-target.15140
- 19. Nencha, U., Rahimian, A., Giry, M et al. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. J. Neurooncol. 2016,126, 441-446.
- 20. Basolo, F., Torregrossa, L., Giannini, R et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J. Clin. Endocrinol. Metab. 2010,95, 4197-4205.
- 21. Xing, M., Tufano, R.P., Tufaro, A.P et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2004,89, 2867-2872.
- 22. Tufano, R.P., Teixeira, G. V, Bishop, J et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Med. 2012,91, 274-286. https://doi.org/10.1097/MD.0b013e31826a9c71
- 23. Kim, J., Giuliano, A.E., Turner, R.R et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann. Surg. 2006,244, 799.
- 24. Yan, C., Huang, M., Li, X et al. Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma. Endocr. Connect. 2019,8, 988-996. https://doi.org/10.1530/EC-19-0246
- 25. Xing, M., Alzahrani, A.S., Carson, K.A et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015,33, 42-50. https://doi.org/10.1200/jco.2014.56.8253
- 26. Kebebew, E., Weng, J., Bauer, J et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 2007,246, 461-466. https://doi.org/10.1097/SLA.0b013e318148563d
- 27. Kurtulmus, N., Duren, M., Ince, U et al. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine. 2012,42, 404-410. https://doi.org/10.1007/s12020-012-9651-x
- 28. Kim, S.K., Woo, J.-W., Lee, J.H et al. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma. Endocr. Relat. Cancer. 2016,23, 27-34. https://doi.org/10.1530/ERC-15-0408
- 29. Kim, T.H., Park, Y.J., Lim, J.A et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012,118, 1764-1773. https://doi.org/10.1002/cncr.26500
- 30. Haugen, B.R. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer. 2017,123, 372-381. https://doi.org/10.1002/cncr.30360
- 31. Henke, L.E., Pfeifer, J.D., Ma, C et al. BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma. Cancer Med. 2015,4, 791-799. https://doi.org/10.1002/cam4.417
- 32. Wang, T.S., Sosa, J.A. Thyroid surgery for differentiated thyroid cancer – recent advances and future directions. Nat. Rev. Endocrinol. 2018,14, 670-683. https://doi.org/10.1038/s41574-018-0080-7
- 33. Li, G., Pan, T., Guo, D., Li, L.-C. Regulatory Variants and Disease: The E-Cadherin -160C/A SNP as an Example. Mol. Biol. Int. 2014,2014, 967565. https://doi.org/10.1155/2014/967565
- 34. Epstein, D.J. Cis-regulatory mutations in human disease. Brief. Funct. Genomic. Proteomic. 2009,8, 310-316. https://doi.org/10.1093/bfgp/elp021
- 35. Heidenreich, B., Kumar, R. Altered TERT promoter and other genomic regulatory elements: occurrence and impact. 2017,141, 867-876. https://doi.org/10.1002/ijc.30735
- 36. Ko, E., Seo, H.-W., Jung, E.S et al. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer. Oncotarget. 2016,7, 684-699. https://doi.org/10.18632/oncotarget.6331
- 37. Rachakonda, P.S., Hosen, I., de Verdier, P.J et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl. Acad. Sci. U. S. A. 2013,110, 17426-17431. https://doi.org/10.1073/pnas.1310522110
- 38. Hirokawa, T., Arimasu, Y., Chiba, T et al. Clinicopatho-logical significance of the single nucleotide polymorphism, rs2853669 within the TERT promoter in papillary thyroid carcinoma. Pathol. Int. 2020,70, 217-223. https://doi.org/10.1111/pin.12900
- 39. Argyropoulou, M., Veskoukis, A.S., Karanatsiou, P.-M et al. Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population. Pathol. Oncol. Res. 2020,26, 347-354. https://doi.org/10.1007/s12253-018-0497-2
- 40. Qasem, E., Murugan, A.K., Al-Hindi, H et al. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocr. Relat. Cancer. 2015,22, 901-908. https://doi.org/10.1530/ERC-15-0396
- 41. Huang, M., Yan, C., Xiao, J et al. Relevance and clinicopatho-logic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Diagn. Pathol. 2019,14, 74. https://doi.org/10.1186/s13000-019-0849-6
- 42. Vuong, H.G., Altibi, A.M.A., Duong, U.N.P., Hassell, L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin. Endocrinol. (Oxf). 2017, 87, 411-417. https://doi.org/10.1111/cen.13413